Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF), a Canadian developer of pharmaceutical-grade contrast media, announced it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility. The company is conducting a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites, with key criteria including proximity to iodine brine sources, logistics, infrastructure, access to skilled labor, and government incentive packages.
Shortlisted jurisdictions in Oklahoma and Texas offer strategic advantages, including proximity to Voyageur's iodine extraction initiatives in Oklahoma's Anadarko Basin, robust transportation infrastructure (rail, major highways, and port access), access to skilled labor and municipal water supply, and strong local, state, and federal incentives supporting advanced manufacturing and pharmaceutical onshoring.
The planned facility will receive concentrated iodine liquor from Voyageur's proprietary closed-loop Streamlined Iodine Process and high-purity barite from the Frances Creek project. Unlike conventional manufacturers that depend on imported iodine flakes or intermediates, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security for U.S. hospitals and government customers.
Key anticipated project highlights include cost leadership through vertical integration, significant funding and incentive opportunities, creation of 150–250 direct high-skilled jobs, and substantial economic activity and tax revenue. The facility is expected to enable efficient management of iodine and barium contrast production while supporting iodine supply for Voyageur's collaboration with Bayer on the Oklahoma iodine prill project.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: "This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits."
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing and regulatory approvals. This announcement builds on Voyageur's ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use.
The implications of this announcement are significant for the medical imaging industry and U.S. healthcare supply chain. Currently, the U.S. relies heavily on imported iodine and contrast media, which are subject to geopolitical risks and supply disruptions. Voyageur's integrated facility would create a secure, domestic source of these critical drugs, reducing shortage risks for hospitals and patients. Additionally, the vertical integration is expected to lower production costs, potentially reducing healthcare costs. The project aligns with U.S. priorities for domestic critical minerals, pharmaceutical onshoring, and rural economic development, and could serve as a model for reshoring other essential pharmaceutical manufacturing.
Voyageur Pharmaceuticals is a Canadian company focused on becoming a low-cost, vertically integrated producer of barium and iodine APIs and finished imaging contrast agents. The company has developed five barium contrast products with Health Canada licenses and is positioned to become North America's first vertically integrated manufacturer of both barium and iodine contrast media.
